Replies to post #79270 on Biotech Values

[DewDiligence]

Unlike HIV, where entry inhibitors (PFE’s Selzentry, Roche’s Fuzeon) are on the market, entry inhibitors for HCV have a long way to go. I’m almost certain GILD is working on one, although GILD has never stated this explicitly.